Cargando…

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia

Detalles Bibliográficos
Autores principales:	Stanulla, Martin, Schewe, Denis M., Bornhauser, Beat, Bourquin, Jean-Pierre, Eckert, Cornelia, Eberl, Wolfgang, Wolf, Saskia, Wolf, Julian, Vogiatzi, Fotini, Bergmann, Anke K., Cario, Gunnar, Beier, Rita, Sauer, Martin, Kratz, Christian P., Maecker-Kolhoff, Britta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977701/ https://www.ncbi.nlm.nih.gov/pubmed/36651980 http://dx.doi.org/10.1007/s00277-023-05083-y

Ejemplares similares

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Repurposing anthelmintic agents to eradicate resistant leukemia
por: Mezzatesta, Caterina, et al.
Publicado: (2020)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation
por: Maier, Stefanie, et al.
Publicado: (2022)

Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia
por: Zaliova, Marketa, et al.
Publicado: (2020)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022)

Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation
por: Mynarek, Martin, et al.
Publicado: (2013)

Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
por: Eiz-Vesper, Britta, et al.
Publicado: (2013)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
por: Nakamura, Ayano, et al.
Publicado: (2021)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
por: Mistry, Jayna J, et al.
Publicado: (2021)

Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support
por: Boutter, Jeannette, et al.
Publicado: (2014)

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
por: Voruz, Sophie, et al.
Publicado: (2021)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
por: Seyfried, Felix, et al.
Publicado: (2019)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

High genetic stability of co-circulating human adenovirus type 31 lineages over 59 years
por: Götting, Jasper, et al.
Publicado: (2022)

Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies
por: Tischer, Sabine, et al.
Publicado: (2011)

Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes
por: Bieling, Maren, et al.
Publicado: (2017)

AP-1 Transcription Factor Complex Members FOSB and FOS are Linked With CNS Infiltration and Inferior Prognosis in Childhood T-ALL
por: Spory, Lea, et al.
Publicado: (2023)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

PDX models recapitulate the genetic and epigenetic landscape of pediatric T‐cell leukemia
por: Richter‐Pechańska, Paulina, et al.
Publicado: (2018)

Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection
por: Tischer, Sabine, et al.
Publicado: (2016)

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2023)

P322: DECIPHERING THE UNDERLYING MOLECULAR COMPLEXITY OF THE IKZF1PLUS SIGNATURE
por: Lühmann, Jonathan, et al.
Publicado: (2023)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics
por: Chouvarine, Philippe, et al.
Publicado: (2021)

Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution
por: Richter-Pechańska, Paulina, et al.
Publicado: (2022)

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
por: Choudhry, Priya, et al.
Publicado: (2019)

MicroRNA expression in Epstein-Barr virus-associated post-transplant smooth muscle tumours is related to leiomyomatous phenotype
por: Jonigk, Danny, et al.
Publicado: (2013)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads
por: Mangare, Caroline, et al.
Publicado: (2019)

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
por: Erarslan‐Uysal, Büşra, et al.
Publicado: (2020)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression
por: Bak, Szilvia, et al.
Publicado: (2018)

Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients
por: Schulze Lammers, Friederike C., et al.
Publicado: (2022)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qcunb33l705dqd9vkv9n5asmip